Skip to main content
OpenTrials
Completed

NCT Number: NCT02814929

Incidence, Risk Factors and Severity of Retinopathy of Prematurity (ROP) in Turkey

The study includes preterm infants who are being screened for ROP between April 1,2016 and April 30, 2017 in 69 neonatal intensive care units (NICUs) in Turkey. Infants with birth weight (BW) of ≤1500 g or ≤32 weeks' gestation and those with a BW of greater than 1500 g or gestational age (GA) >32 weeks with an unstable clinical course are included. The incidence of any ROP, severe ROP and treatment modalities will be determined. The risk factors for ROP development will also be evaluated.

Completed

Looking for future studies?

Notify Me

Key information

Age range

28 day and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Etlik Zubeyde Hanim Womens' Health and Teaching Hospital

Ankara, Keçi̇ören, 06100, Turkey (Türkiye)

About this study

This study, promoted by the "Turkish Neonatology Society", involved preterm infants who are being screened for ROP between April 1, 2016 and April 30, 2017 in level III Turkish NICUs.

An electronic questionnaire is being filled by certified neonatologists in Turkey via a special network. Neonatologists working in 69 centers who agreed to participate in this study provide their data regarding the ROP in their NICU. The medical records of retinal examinations of preterm infants who met the screening criteria will be evaluated.

A case report form for each patient will be filled including risk factors for the development of ROP such as gestational age, birth weight, small for gestational age (SGA), gender, multiple gestation, antenatal steroid therapy, invitro fertilisation, preeclampsia/eclampsia, infants of diabetic mother, chorioamnionitis, resuscitation in delivery room, respiratory distress syndrome (RDS), duration of mechanical ventilation and oxygen therapy, intracranial hemorrhage, hemodynamically significant patent ductus arteriosus (PDA), early/late sepsis, necrotising enterocolitis (NEC), number of blood transfusions, bronchopulmonary dysplasia (BPD), weight gain at postnatal 28th days and breastfeeding.

Risk factors for developing ROP will be evaluated. Multivariate analysis will be performed among significant variables.

In addition, the incidence of any ROP, severe ROP in relation to GA and BW and treatment modalities will be determined. Severe ROP is defined as ROP requiring treatment.

Since Turkey is receiving many refugees in recent years, the investigators also planned to evaluate the incidence and risk factors for developing ROP in preterm babies of refugees.

Ophthalmologic examination is continued until full vascularisation. So, the maximum stage of ROP detected for every infant will be reported. Data from 69 NICUs will be pooled together and analyzed.

The "International Classification of ROP" guidelines are used to record stage of disease, location by zone, signs of plus disease and signs of regression. Criteria for treatment of ROP are based on the Early Treatment for Retinopathy of Prematurity (ETROP) recommendation. Confirmed forms are also assigned by the parents before the initial screening and treatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Infants with BW ≤1500 g or ≤32 weeks' gestation and those with a BW of greater than 1500 g or GA >32 weeks requiring cardiorespiratory support and who were determined by the attending clinician to be at risk for ROP, are included.

Exclusion criteria

  • Neonates who died before the first ROP examination are excluded from the study.

Treatment and study plan

Primary outcomes

  1. Incidence of ROP in Turkey

    Time frame: 12 months

    Incidence of ROP and severe ROP in relation to GA and BW in Turkey

Secondary outcomes

  1. The association of antenatal corticosteroid administration with ROP

    Time frame: 12 months

  2. The role of sepsis in infants in the development of ROP

    Time frame: 12 months

    Culture proven and clinical early and late sepsis will be evaluated

  3. The relationship between rate of postnatal weight gain and severity of ROP

    Time frame: 12 months

  4. The relationship between breastfeeding and ROP development

    Time frame: 12 months

  5. ROP in SGA premature infants

    Time frame: 12 months

    Comparison of ROP in SGA infants with those of appropriate size for GA

  6. ROP in multiple births

    Time frame: 12 months

    Comparison of the frequency and severity of ROP among singleton and multiple-birth neonates

  7. The role of transfusions in ROP development

    Time frame: 12 months

  8. Duration of oxygen therapy among infants with and without ROP

    Time frame: 12 months

  9. Number of patients requiring laser photocoagulation treatment

    Time frame: 12 months

  10. Number of patients requiring vitreoretinal surgery

    Time frame: 12 months

  11. Number of patients requiring anti-vascular endothelial growth factor treatment

    Time frame: 12 months

Other outcomes

  1. Incidence of ROP in preterm babies of refugees in Turkey

    Time frame: 12 months

    Incidence of any ROP and severe ROP in relation to GA and BW in preterm babies of refugees

Sponsors and collaborators

Lead sponsor

Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital

Other

Collaborators

  • Acibadem Atakent University Hospital
  • Adana Numune Training and Research Hospital
  • Ankara Guven Hospital
  • Ankara University
  • Ataturk University
  • Ataşehir Kadıkoy Sifa Hospital
  • Aydin Adnan Menderes University
  • Bagcilar Training and Research Hospital
  • Baskent University
  • Baskent University Ankara Hospital
  • Bezmialem Vakif University
  • Bulent Ecevit University
  • Canakkale 18 Mart University
  • Cengiz Gokcek Women's and Children's Hospital
  • Cukurova University
  • Denizli Devlet Hastanesi
  • Denizli Ozel Saglik Hospital
  • Dicle University
  • Dokuz Eylul University
  • Dortcelik Children Hospital
  • Doruk Bursa Hospital
  • Dr. Behcet Uz Children's Hospital
  • Dr. Lutfi Kirdar Kartal Training and Research Hospital
  • Ege University
  • Erzurum Nenehatun Maternity Hospital
  • Eskisehir Osmangazi University
  • Faruk Sukan Maternity and Children Hospital
  • Firat University
  • Hacettepe University
  • Inonu University
  • Istanbul Medeniyet University
  • Istanbul Medipol University Hospital
  • Istanbul University
  • Kahramanmaras Megapark Hospital
  • Kahramanmaras Sutcu Imam University
  • Kanuni Sultan Suleyman Training and Research Hospital
  • Karadeniz Technical University
  • Kecioren Education and Training Hospital
  • Konya Baskent University
  • Konya Meram State Hospital
  • Koç University
  • Kırıkkale University
  • Marmara University
  • Medical Park Gaziantep Hospital
  • Mersin Maternity Hospital
  • Mustafa Kemal University
  • Muğla Sıtkı Koçman University
  • NCR International Hospital
  • Necmettin Erbakan University
  • Ondokuz Mayıs University
  • Ozel Medova Hospital
  • Pamukkale University
  • Sami Ulus Maternity and Children Hospital
  • Selcuk University
  • Sisli Hamidiye Etfal Training and Research Hospital
  • Suleymaniye Birth And Women's Health Education And Research Hospital
  • TC Erciyes University
  • Tepecik Training and Research Hospital
  • Tokat Gaziosmanpasa University
  • Trabzon Kanuni Education and Research Hospital
  • Trakya University
  • Uludag University
  • Umraniye Education and Research Hospital
  • University of Gaziantep
  • Yuksek Ihtisas University
  • Yuzuncu Yil University
  • Zekai Tahir Burak Women's Health Research and Education Hospital
  • Zeynep Kamil Maternity and Pediatric Research and Training Hospital

Registry information

Official study title

Incidence, Risk Factors and Severity of Retinopathy of Prematurity (ROP) in Turkey: A Prospective Multicenter Study Including 69 NICUs

Acronym: TR-ROP

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Jun 28, 2016
Registry last updated
Sep 11, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.